The Expression Regulation and Cancer-Promoting Roles of RACGAP1.
1/5 보강
RACGAP1 is a Rho-GTPase-activating protein originally discovered in male germ cells to inactivate Rac, RhoA and Cdc42 from the GTP-bound form to the GDP-bound form.
APA
Lin J, Zhu Y, et al. (2024). The Expression Regulation and Cancer-Promoting Roles of RACGAP1.. Biomolecules, 15(1). https://doi.org/10.3390/biom15010003
MLA
Lin J, et al.. "The Expression Regulation and Cancer-Promoting Roles of RACGAP1.." Biomolecules, vol. 15, no. 1, 2024.
PMID
39858398
Abstract
RACGAP1 is a Rho-GTPase-activating protein originally discovered in male germ cells to inactivate Rac, RhoA and Cdc42 from the GTP-bound form to the GDP-bound form. GAP has traditionally been known as a tumor suppressor. However, studies increasingly suggest that overexpressed RACGAP1 activates Rac and RhoA in multiple cancers to mediate downstream oncogene overexpression by assisting in the nuclear translocation of signaling molecules and to promote cytokinesis by regulating the cytoskeleton or serving as a component of the central spindle. Contradictorily, it was also reported that RACGAP1 in gastric cancer could inactivate Rac and RhoA. In addition, studies have revealed that RACGAP1 can be a biomarker for prognosis, and its role in reducing doxorubicin sensitivity poses difficulties for treatment, while the current drug targets mainly focus on its downstream molecule. This article mainly reviews the expression regulation of RACGAP1 and its cancer-promoting functions through oncogene expression mediation and Rho-GTPase activation.
MeSH Terms
Humans; GTPase-Activating Proteins; Neoplasms; Gene Expression Regulation, Neoplastic; Animals; Signal Transduction; rhoA GTP-Binding Protein
같은 제1저자의 인용 많은 논문 (5)
- Modified technique of chin augmentation with MEDPOR for Asian patients.
- Current status and prospects of methylthioadenosine phosphorylase/protein arginine methyltransferase 5 target therapy.
- Feasibility and preliminary efficacy of an art-making program to manage fear of cancer recurrence (AM-I-FCR) in lung cancer patients: a randomized controlled pilot study.
- Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data.
- Efficacy and safety of Osimertinib and other third-generation EGFR TKIs in advanced NSCLC: a systematic review and meta-analysis.